Alpha Wealth Funds, LLC, an investment management company, released its Q3 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund returned 4.96% in September, ...

Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...

GameSpot may get a commission from retail offers. We are fast approaching the end to another Fortnite chapter, and that means it's nearly time for a huge live event that will introduce a new era for ...

For the fastest way to join Tom's Guide Club enter your email below. We'll send you a confirmation and sign you up to our newsletter to keep you updated on all the latest news. By submitting your ...

Nvidia (NVDA) may post sales of $56.8B next week according to Citi. Multiple firms upgraded their price targets ahead of earnings. Sunrun (RUN) was upgraded to buy by Guggenheim with a $27 price ...

Fintel reports that on November 10, 2025, Leerink Partners upgraded their outlook for Eli Lilly and (NYSE:LLY) from Market Perform to Outperform. Analyst Price Forecast Suggests 0.26% Upside As of ...

Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy, which perhaps explains the former's triple-digit GLP-1 revenue growth on a YoY basis. This is ...

Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, ...

Offers a broad portfolio of pharmaceuticals targeting diabetes, oncology, immunology, neuroscience, and other therapeutic areas; key products include Zepbound ...

In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the ...